Last reviewed · How we verify
High dose gonadotropins
High dose gonadotropins stimulate the ovaries to produce multiple mature eggs for assisted reproductive procedures.
High dose gonadotropins stimulate the ovaries to produce multiple mature eggs for assisted reproductive procedures. Used for Controlled ovarian hyperstimulation for in vitro fertilization (IVF), Assisted reproductive technology (ART) procedures.
At a glance
| Generic name | High dose gonadotropins |
|---|---|
| Also known as | Gonal F or Follistim |
| Sponsor | Weill Medical College of Cornell University |
| Drug class | Gonadotropin |
| Target | FSH receptor, LH receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
Gonadotropins (FSH and/or hCG) are hormones that directly stimulate follicle development and maturation in the ovaries during controlled ovarian hyperstimulation. This allows retrieval of multiple oocytes for in vitro fertilization or other fertility treatments. The high doses override natural feedback inhibition to achieve supraphysiologic hormone levels and multifollicular development.
Approved indications
- Controlled ovarian hyperstimulation for in vitro fertilization (IVF)
- Assisted reproductive technology (ART) procedures
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Injection site reactions
- Headache
- Abdominal bloating and discomfort
- Nausea
Key clinical trials
- Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids (PHASE1, PHASE2)
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (PHASE2, PHASE3)
- Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer (PHASE2)
- Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (NA)
- Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC (PHASE2)
- Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring (PHASE1, PHASE2)
- Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (PHASE2, PHASE3)
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High dose gonadotropins CI brief — competitive landscape report
- High dose gonadotropins updates RSS · CI watch RSS
- Weill Medical College of Cornell University portfolio CI